Cohance Lifesciences to Hold 7th AGM on September 19, 2025; Agenda Includes Financials & Director Matters
The announcement is a standard disclosure for an upcoming Annual General Meeting and its agenda, which includes routine corporate governance matters like adopting financial statements and director re-appointment, with no immediate material impact on the company's operations or financials.
The announcement details the schedule and agenda for a routine Annual General Meeting, including adoption of financial statements, re-appointment of a director, and approval of remuneration, without any specific positive or negative financial implications.
* Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) has announced that its 7th Annual General Meeting (AGM) will be held on Friday, September 19, 2025, at 02:30 p.m. IST. * The AGM will be conducted through Video Conference (VC) / Other Audio Visual Means (OAVM). * Key agenda items for the AGM include: * Adoption of the audited standalone and consolidated financial statements for the financial year ended March 31, 2025. * Re-appointment of Dr. V. Prasada Raju (DIN: 07267366) as a Director, who retires by rotation. * Approval for payment of remuneration to Dr. V Prasada Raju, Managing Director, for the remaining term of his office. * Appointment of M/s Makarand M. Joshi & Co., Company Secretaries, as Secretarial Auditors for a term of five consecutive years, commencing from the financial year 2025-26 till financial year 2029-30. * The cut-off date for e-voting is Friday, September 12, 2025. * Remote e-voting will start on Monday, September 15, 2025, at 9:00 a.m. IST and end on Thursday, September 18, 2025, at 5:00 p.m. IST. * The Notice of the 7th AGM and the Annual Report for the financial year 2024-25 have been circulated to shareholders electronically and are available on the Company’s website as well as on the websites of BSE and NSE.
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under agm-egm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.